Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
The Drug Enforcement Administration (DEA) raided medical clinics, pharmacies and other locations across the South on Wednesday as part of a DEA attempt to thwart illegal prescription drug sales.
read more
Novartis has announced that the Phase III study of Afinitor® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint.
read more
EMD Millipore and Singulex have entered into a definitive agreement under which EMD Millipore will control and manage the Singulex Life Science Research business.
read more
Eight physician groups sent a letter to U.S. Food and Drug Administration (FDA) Commissioner Stephen Ostroff underscoring the need to ensure that biosimilar product labeling contains all needed data for physicians to make appropriate prescribing ...
read more
The U.S. Food and Drug Administration's (FDA) recent approval of Zarxio (filgrastim-sndz) -- the first biosimilar product approved in the United States -- points toward growth in the contract manufacturing organization (CMO) industry, according to ...
read more
Abbvie has completed its $21B buyout of Pharmacyclics.
read more
An international team including scientists from Albert Einstein College of Medicine of Yeshiva University and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has identified the molecular "lock" that the deadly Ebola virus ...
read more
As the pharmaceutical industry embraces increased transparency, medical publications teams require the resources to support a growing demand for abstracts and manuscripts. According to a recent study by life sciences intelligence firm Cutting Edge ...
read more
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June ...
read more
Sticky plaque gets the most attention, but now healthy seniors at risk of Alzheimer's are letting scientists peek into their brains to see if another culprit is lurking.
read more
Halozyme Therapeutics and Ventana Medical Systems, a member of the Roche Group, announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's ...
read more
Theravance Biopharma and SciClone Pharmaceuticals have entered into a development and commercialization agreement granting SciClone exclusive development and commercial rights for the antibiotic VIBATIV® (telavancin) in China and certain adjacent ...
read more
The Guardian Research Network and Molecular Health have announced a collaboration designed to provide therapeutic clinical trial access and molecular diagnostic decision support to the majority of cancer patients living in U.S. communities.
read more
AstraZeneca and Eli Lilly and Company have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab ...
read more
ALBANY, N.Y. (AP) — A federal appeals court has ruled that drug manufacturer Actavis PLC's attempted switch of patented Alzheimer's medication, which halted distribution of the old drug before its patent expires this summer, violates U.S. antitrust ...
read more